Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by PET/CT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00256490|
Recruitment Status : Unknown
Verified November 2005 by Université de Sherbrooke.
Recruitment status was: Recruiting
First Posted : November 21, 2005
Last Update Posted : November 21, 2005
Patients affected with non-Hodgkin’s large B-cell lymphoma are treated by chemotherapy. The evaluation of the response to this treatment is made by Positron Emission Tomography (PET/CT) in many centres where this technology is available. Presently PET scans and CT scans are being performed before treatment, after 4 cycles of chemotherapy and a few months after the end of treatment.
The goal of this study is to determine if it is possible to evaluate the efficiency of chemotherapy treatments after one cycle of treatment instead of waiting after 4 cycles, using a new scanner that combines PET and CT modalities. Data available from studies on these combined exams suggest that PET/CT helps to rapidly evaluate the response of the chemotherapy treatment. We also want to verify if some pathological characteristics measured from tumor cells will enable doctors to predict in advance the response to treatment.
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma, Large-Cell||Procedure: PET/CT 20 days after the first cycle of chemotherapy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||82 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by Positron Emission Tomography Coupled With Computed Tomography (PET/CT)|
|Study Start Date :||November 2005|
|Study Completion Date :||November 2009|
- Disease free survival at 2 years
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00256490
|Contact: Eric Turcotte, MD, FRCPC||819-346-1110 ext firstname.lastname@example.org|
|Contact: Chantal Langevin, inf||819-346-1110 ext email@example.com|
|Centre Hospitalier Universitaire de Sherbrooke||Recruiting|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Contact: Eric Turcotte, MD, FRCPC 819-346-1110 ext 11887 firstname.lastname@example.org|
|Principal Investigator:||Eric Turcotte, MD, FRCPC||Centre de recherche du Centre hospitalier universitaire de Sherbrooke|
|Principal Investigator:||Francois Bénard, MD, FRCPC||Centre de recherche du Centre hospitalier universitaire de Sherbrooke|
|Principal Investigator:||Virginie Bruneau, MD||Centre de recherche du Centre hospitalier universitaire de Sherbrooke|